tiprankstipranks
Senzime AB (SE:SEZI)
:SEZI
Sweden Market
Want to see SE:SEZI full AI Analyst Report?

Senzime AB (SEZI) Earnings Dates, Call Summary & Reports

2 Followers

Earnings Data

Report Date
Aug 21, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
Last Year’s EPS
-0.24
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Apr 22, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook: the company reported strong underlying operational momentum (notably sensor growth, a 1M monitored‑patient milestone, margin improvement, new business models like TetraGraph‑as‑a‑Service, TetraCom and important customer wins) while acknowledging a temporary Q1 growth dip driven by delayed U.S. deals, FX and tariff headwinds and some regional regulatory timing issues. Management emphasizes cost discipline, a solid pipeline, available funding and confidence in meeting full‑year objectives, but execution (recovering delayed deals, FX/tariff resolution and regulatory rollouts) is needed to realize targets.
Company Guidance
The company reiterated that full‑year 2026 targets remain intact and reiterated sales growth guidance “in line with previous years” (historical 5‑year CAGR ~60%), with an objective to be cash‑flow positive by Q4 2026; management expects a Q2 bounce and continued margin expansion (underlying gross margin Q1 69.2%, reported 63.1%) and flat‑to‑lower operating expenses (Q1 OpEx SEK 35.6m, down ~5% YoY and ~17.5% vs Q4). Key operational metrics cited to support the outlook include global quarterly shipments of 376 TetraGraphs (vs 443 a year ago), cumulative shipments >5,500, 246 monitors shipped in the U.S. (120 on the new TetraGraph‑as‑a‑Service model), sensor volumes passing 1 million monitored patients (rolling‑12M sensor growth ~27% YoY; sensor sales reported +40% in constant currency earlier), Europe disposable growth ~60%, U.S. business +11% in local currency (U.S. sensors +55% but reported U.S. sales down ~5%, ~SEK 0.75m, due to FX), cash SEK 55.3m at quarter‑end plus an available credit facility (SEK 50m facility, SEK 7.5m drawn, ~SEK 42.5m remaining), cash flow improvement +33%, and tariff exposure (~SEK 5m paid) that management is pursuing to recover — all of which underpin the confidence in achieving the year‑end targets.
Strong Sensor Sales Growth and Recurring Revenue
Sensor sales increased ~40% in constant currencies; rolling 12‑month sensor volume grew ~27%. Company passed 1,000,000 monitored patients milestone, strengthening recurring revenue (sensors are the majority of revenues and drive gross margin leverage).
U.S. Disposable Performance and TetraGraph-as-a-Service Traction
U.S. disposables grew ~55% in local currency and overall U.S. business grew ~11% in local currency. Shipped 246 TetraGraphs in the U.S. during the quarter, of which 120 were deployed under the new TetraGraph‑as‑a‑Service model. First two As‑a‑Service deals closed in about half the time of a typical capital sale and support higher long‑term sensor margins.
Installed Base Expansion and Product Deliveries
Total shipped TetraGraphs surpassed ~5,500 units to date. Q1 shipments were 376 units (versus 443 prior year). Notable pediatric progress with 65 TetraGraphs delivered to pediatric operating rooms and a threefold increase in pediatric sensor units in the quarter.
Underlying Gross Margin Improvement
Underlying gross margin improved to ~69.2% (reported margin 63.1% after FX/tariff effects). Management is increasing pricing (U.S. ASPs up ~5%) and expects further margin expansion from scale and pricing actions.
Cost Discipline and Cash / Cash‑Flow Improvements
Operating expenses declined ~5% year‑over‑year and ~17.5% versus Q4. Operating cash flow improved ~33% (still negative), EBITDA slightly better, net earnings improved (partly FX driven). Cash of SEK 55.3m and access to additional credit (SEK ~42.5m available) provide runway.
Clinical Guideline Support and Product Innovation
Publication of new European pediatric guideline recommending quantitative (preferably EMG‑based) monitoring supports adoption. Launched TetraCom (EHR connectivity) enabling integration with Epic/Oracle and partners (Philips, Masimo, GE, Mindray), creating new monetization/recurring service opportunities.
Large Customer Wins and Strong Pipeline
Secured important U.S. wins including Ivy League hospitals, a major IDN expansion with ~SEK 6m run rate/year, a large hospital extension in Florida, a major children's hospital in Texas, and ~250 hospitals as customers in the U.S. Management reports a strong pipeline and maintains full‑year targets.

Senzime AB (SE:SEZI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SE:SEZI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 21, 2026
2026 (Q2)
- / -
-0.244
Apr 22, 2026
2026 (Q1)
- / -0.14
-0.2645.00% (+0.12)
Feb 18, 2026
2025 (Q4)
- / -0.27
-0.2-36.50% (-0.07)
Oct 29, 2025
2025 (Q3)
-0.12 / -0.16
-0.2637.69% (+0.10)
Jul 18, 2025
2025 (Q2)
-0.17 / -0.24
-0.2812.86% (+0.04)
Apr 22, 2025
2025 (Q1)
-0.24 / -0.26
-0.2-30.00% (-0.06)
Feb 17, 2025
2024 (Q4)
-0.20 / -0.20
-0.333.33% (+0.10)
Nov 06, 2024
2024 (Q3)
-0.23 / -0.26
-0.313.33% (+0.04)
Aug 26, 2024
2024 (Q2)
-0.20 / -0.28
-0.430.00% (+0.12)
May 07, 2024
2024 (Q1)
-0.30 / -0.20
-0.3441.18% (+0.14)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SE:SEZI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 22, 2026
kr5.66kr4.76-15.90%
Feb 18, 2026
kr4.41kr4.52+2.49%
Oct 29, 2025
kr5.90kr6.00+1.69%
Jul 18, 2025
kr5.48kr5.85+6.75%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Senzime AB (SE:SEZI) report earnings?
Senzime AB (SE:SEZI) is schdueled to report earning on Aug 21, 2026, TBA (Confirmed).
    What is Senzime AB (SE:SEZI) earnings time?
    Senzime AB (SE:SEZI) earnings time is at Aug 21, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Senzime AB stock?
          The P/E ratio of Senzime AB is N/A.
            What is SE:SEZI EPS forecast?
            Currently, no data Available